Core Viewpoint - The announcement of the New Drug Application (NDA) acceptance for TY-9591, a new generation EGFR-TKI inhibitor targeting brain metastases from non-small cell lung cancer (NSCLC), marks a significant milestone for the company and the treatment landscape for lung cancer patients in China [1][3]. Group 1: Drug Development and Clinical Trials - The NDA for TY-9591 has been officially accepted by the National Medical Products Administration (NMPA) in China, making it the first new generation EGFR-TKI specifically for lung cancer brain metastases [1][3]. - The NDA submission is based on results from a pivotal clinical study (ESAONA) that evaluated the efficacy and safety of TY-9591 compared to Osimertinib in NSCLC patients with brain metastases [3][4]. - The interim analysis of the ESAONA study showed an intracranial objective response rate (iORR) of 92.8% for the TY-9591 group compared to 76.1% for the Osimertinib group, indicating a statistically significant difference [4]. Group 2: Company Strategy and Future Plans - The submission of the NDA for TY-9591 represents a critical milestone for the company, indicating its entry into the commercialization phase and its commitment to addressing unmet clinical needs in cancer treatment [6][8]. - The company plans to continue exploring combination therapies and further clinical research to meet the clinical demands of patients with advanced NSCLC [5][6]. - The company has developed over ten innovative products since its establishment in 2017, focusing on next-generation kinase inhibitors to fulfill unmet clinical needs in cancer treatment [8].